Compare Inovio Pharmaceuticals Inc (INO) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Alliant Energy Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Alliant Energy Corporation trades at $69.9 (market cap $17.78B). The key difference: Alliant Energy Corporation is far larger — about 226.4× Inovio Pharmaceuticals Inc's market cap, and Alliant Energy Corporation pays a 3.12% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | LNT | |
|---|---|---|
Market Cap | $78.55M | $17.78B |
Sector | Health | Utilities |
52-Week High | $2.87 | $78.03 |
52-Week Low | $0.66 | $63.62 |
Enterprise Value | $49.56M | $29.88B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Alliant Energy (LNT) trades at $68.21, down 1.67% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.65, beating estimates, and reaffirmed full-year guidance. Revenue grew to $4.36B in 2025, with net income margin at 18.45%. Analyst consensus is a Buy with a $77.67 price target, indicating potential upside. Recent news highlights institutional activity, including Assenagon Asset Management increasing its stake by 339.9% as of August 12, 2026.
LNT presents a stable investment opportunity with consistent earnings beats and a dividend yield, but faces risks from rising debt levels and bearish technical trends. The stock's valuation metrics, including a P/E of 21.7, are reasonable for the utilities sector. Upside is supported by analyst targets, while headwinds include higher interest costs and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
